Current Report Filing (8-k)
January 27 2020 - 5:12PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR
15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported) January 21, 2020
NANOVIRICIDES, INC.
|
(Exact Name of Registrant as Specified in Its Charter)
|
Nevada
|
001-36081
|
76-0674577
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
|
1 Controls Drive,
Shelton, Connecticut 06484
|
06484
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(203) 937-6137
|
(Registrant's Telephone Number, Including Area Code)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered:
|
Common Stock
|
|
NNVC
|
|
NYSE-American
|
Item 1.01 Entry into a Material Definitive
Agreement.
Underwritten Public Offering
On January 21, 2020,
NanoViricides, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting
Agreement”) with Aegis Capital Corp. Pursuant to the terms and conditions of the Underwriting Agreement, we agreed to
issue and sell 2,500,000 shares of our common stock, par value $0.001 per share (the “Underwritten Shares”), at a
price to the public of $3.00 per share, a 30% discount to the five (5) day average trading price of the common stock. Pursuant to the Underwriting Agreement, we also granted the underwriter an option to purchase up
to an additional 375,000 shares of our common stock (together with the Underwritten Shares, the “Shares”) within
45 days after the date of the Underwriting Agreement to cover over-allotments, if any. The Final Prospectus for the
offering was filed with the U.S. Securities and Exchange Commission pursuant to Rule 424(b)(1) of the Securities Act of
1933, as amended, on January 23, 2020.
The offering was
consummated on January 25, 2020. The Company sold the Underwritten Shares and the underwriter exercised its option to purchase
an additional 375,000 shares of common stock at the public offering price of $3.00 per share. Aegis
Capital Corp. acted as sole bookrunner for the offering.
The
net proceeds to the Company after underwriter's commission and agreed upon customary fees and expenses were approximately $7.78
million, before deducting the Company's legal and accounting expenses related to the Offering. The Company intends to use the net
proceeds to fund general corporate purposes and to fund ongoing operations and to repay certain accounts payable to related parties.
The Underwriting Agreement contains customary
representations, warranties and covenants made by us. It also provides for customary indemnification by us and the underwriters
for losses or damages arising out of or in connection with the sale of the Shares. In addition, pursuant to the terms of
the Underwriting Agreement, each director and executive officer of our company has entered into an agreement with the representative
of the underwriters not to sell, transfer or otherwise dispose of our securities, subject to certain exceptions, during the 90-day
period following the offering, subject to extension in certain circumstances.
A
copy of the Underwriting Agreement is filed as Exhibit 1.1 to this Form 8-K and is incorporated herein by reference. The
foregoing description of the Underwriting Agreement is not complete and is qualified in its entirety by reference to such exhibit.
Item 8.01 Other Events.
Press Releases for Underwritten
Public Offering
On
January 24, 2020, the Company issued a press release announcing the closing of the Offering. A copy of the press release
is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE
SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO
DULY AUTHORIZED.
|
NANOVIRICIDES, INC.
|
|
|
|
Date: January 27, 2020
|
By:
|
/s/ Anil Diwan
|
|
|
Name: Anil Diwan
|
|
|
Title: Chairman, President
|
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Aug 2024 to Sep 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Sep 2023 to Sep 2024